$15m cap raise Fresh Equities at 24c, page-540

First 540 Last

Share
Profile

Follow
itsagas

13,395 Posts.

1438

05/11/21

16:13

Post #: 57353008
Share

Originally posted by WelshBuffett: ↑

Taylor Collison broker report out - outperform

Phase IIb/III trial designANP’s double blind, European Phase IIb/III study will recruit 114 non-ambulant DMD patients who will be randomised 1:1:1 to receive weekly doses of either placebo, 25mg or 50mg of ATL1102 for 52 weeks. The primary endpoint will be the change in the Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) vs placebo. The trial is expected to commence recruitment in mid CY22 and will enrol at over 30 sites in 9 countries. A futility analysis will be conducted when ~48 patients have completed the week 24 interim PUL 2.0 assessment (mid CY23), leading to a go/no go decision whether to continue the treatment groups or the study itself. The primary endpoint is expected to read out in mid-CY24. At the completion of the 52-week treatment period participants will be invited to enter an open label extension (OLE) study – PDCO has advised that at least 60 participants should be followed for 6 months in the OLE before a marketing approval application is submitted (filing expected to be in H125).Raising $36.8m to fund the pivotal trial to interim analysisANP has raised $20m in a placement at $0.24/sh and is undertaking a non- underwritten 1 for 9.4 entitlement offer to raise a target amount of $16.8m. One free option exercisable at $0.48 will be issued for every 2 new shares. While the issue price of $0.24 was a ~19% discount to the previous closing price, the stock is trading around the issue price, increasing the uncertainty around the uptake of the entitlement offer. If the entitlement offer does not raise the full $16.8m the Phase IIb/III study may not be fully funded to the interim analysis, which may delay the trial or require the company to raise further capital.ATL1102 showed promise in Phase IIa DMD trialIn a Phase IIa trial in 9 non-ambulant DMD patients, subjects treated with 25mg ATL1102 per week for 24 weeks showed an improvement in PUL 2.0 scores, whereas PUL 2.0 scores declined in all 6 other studies of DMD patients that we examined. ATL1102 shows promise as a treatment to reduce inflammation and resultant muscle damage in DMD, which will be investigated in the upcoming pivotal trial at up to twice the dose used in the Phase IIa trial.Valuation per share remains $0.27/shWith funding secured to initiate the pivotal trial we increase our probability of success of ATLL1102 in Europe from 25% to 30%. Assuming 153m shares are issued to raise the targeted $36.8m, our valuation increases from $154m to $197m, but the increased share count sees our per share valuation unchanged at $0.27/sh (undiluted), although fully diluted valuation increases slightly to $0.26/sh.

Expand

This is a Tesearch report done by TC in a June 21
Since then we have EMA approval
Funding for trial$20 mill in the Bank
$ 16 mill to be finalised etc etc
and it’s still a 27 c valuation
Go figure

ANP Price at posting: 22.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

OJC

SPC to merge with Original Juice Co and Nature One Dairy

There are more pages in this discussion • 316 more messages in this thread...

First 540 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change 0.000(0.00%)		Mkt cap ! $90.15M

Open	High	Low	Value	Volume
10.5¢	10.5¢	10.0¢	$177.5K	1.730M

Buyers (Bids)

No.	Vol.	Price($)
3	136159	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	233891	3

View Market Depth

No.	Vol.	Price($)
3	136159	0.100
1	13154	0.099
1	13000	0.098
2	130927	0.097
1	10004	0.096

Price($)	Vol.	No.
0.105	233891	3
0.110	447496	5
0.115	583850	5
0.120	381142	9
0.125	110429	2

Last trade - 16.10pm 02/10/2024 (20 minute delay)

PER (ASX) Chart

$15m cap raise Fresh Equities at 24c, page-540

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

$15m cap raise Fresh Equities at 24c, page-540

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News